Infectious Disease & Vaccines

The history of antibody research has led to modern immunotherapy treatments for infectious diseases.

Small antibodies called nanobodies produced in camels, llamas, and alpacas might help stop the spread of COVID-19, but can they stand up against the competition?

Before its COVID-19 era hype, ivermectin was already a wonder drug for parasitic infections. Its renewed interest underscores the need for effective COVID-19 treatments and communication on proper research study design and analysis.

Increasing cAMP production blocks tuberculosis’ cholesterol metabolism, impairing its pathogenesis in mice.

Cardiologist Sheba Meymandi hopes to prevent the deadly cardiac effects of Chagas disease with increased screening and knowledge of the disease.

Scientists continue to ring alarm bells about the risks associated with the continued misuse of antimicrobials and advocate for innovative treatments, improved surveillance, and greater public health education.

A new delivery system initially developed to treat asthma sends corticosteroids deep into the lungs where COVID-19 infects cells, potentially slowing viral replication.

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.

Researchers employ CRISPR technology in a variety of creative ways to control the spread of vector-borne illnesses.

Respiratory viruses are the most common cause of asthma attacks, but COVID-19 does not send asthma patients to the hospital more often than others. Some researchers suspect that having asthma may actually protect patients from severe COVID-19.